<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Isosulfan blue dye: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Isosulfan blue dye: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Isosulfan blue dye: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12030" href="/d/html/12030.html" rel="external">see "Isosulfan blue dye: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F5577187"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Contrast Agent</li></ul></div>
<div class="block doa drugH1Div" id="F5577217"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e7ba485d-c009-4698-b6d6-d54d3f1604bf">Lymphatic vessel delineation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Lymphatic vessel delineation:</b> SubQ: Inject 0.5 mL into 3 interdigital spaces of each extremity per study; maximum dose: 3 mL (30 mg)</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991812"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50989088"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F5577197"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (2%; affecting abdomen, hands, and neck)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local swelling (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylaxis; skin discoloration (including blue urticaria)</p></div>
<div class="block coi drugH1Div" id="F5577193"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to isosulfan blue, triphenylmethane (or related compounds), or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F5577194"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse events:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discoloration: May cause blue discoloration of urine for 24 hours following administration. May also result in tattoo-like blue coloration of the skin at the injection site (transient or long term).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions, including life-threatening anaphylactic reactions (respiratory distress, shock, angioedema), have occurred. Monitor patients closely for ≥60 minutes following administration. Patients with a history of bronchial asthma, allergies, drug reactions, or prior reactions to triphenylmethane dyes are at higher risk for reactions. Competent personnel should be available to administer emergency care (including resuscitation). For breast cancer sentinel lymph node biopsy, prophylaxis with an IV corticosteroid (hydrocortisone 100 mg, methylprednisolone 20 mg, dexamethasone 4 mg) or diphenhydramine (50 mg IV) or famotidine (20 mg IV) has been used to decrease the severity of hypersensitivity reactions to blue dyes, although the incidence was not decreased (James 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobin: Methemoglobin levels via arterial blood gases (ABG) may be falsely elevated; co-oximetry may be required to accurately assess methemoglobin level.</p>
<p style="text-indent:-2em;margin-left:4em;">• Oxygen saturation: Peripheral oxygenation measurements by pulsoximetry may be falsely low due to isosulfan blue interference (peak interference is 30 minutes after administration; minimal effect by ~4 hours postdose); may require direct determination by ABG analysis.</p></div>
<div class="block foc drugH1Div" id="F5577222"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% (5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1% (5 mL)</p></div>
<div class="block geq drugH1Div" id="F5598929"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16324129"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Isosulfan Blue Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per mL): $245.00 - $254.61</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F5577218"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">SubQ: Single patient use only. Due to precipitation, do not mix with local anesthetics (eg, lidocaine) in same syringe (use separate syringes). Monitor closely for hypersensitivity for ≥60 minutes following administration.</p></div>
<div class="block use drugH1Div" id="F5577188"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Lymphatic vessel delineation:</b> Adjunct to lymphography to delineate lymphatic vessels draining the region of injection in primary and secondary lymphedema of the extremities; chyluria, chylous ascites, or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities.</p></div>
<div class="block cyt drugH1Div" id="F13299549"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F5577202"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F5577190"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. Isosulfan blue 1% injection should be given to a pregnant woman only if clearly needed.</p></div>
<div class="block brc drugH1Div" id="F20681245"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if isosulfan blue is excreted in breast milk. The manufacturer recommends that caution be exercised when administering isosulfan blue to nursing women.</p></div>
<div class="block mop drugH1Div" id="F45759709"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for hypersensitivity reactions for at least 60 minutes following administration. Due to interference with pulse oximetry, monitor arterial blood gases for at least 30 to 240 minutes following administration if need to evaluate oxygenation.</p></div>
<div class="block pha drugH1Div" id="F5577209"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Isosulfan blue binds to serum proteins and is then drained by the regional lymphatic system; blue coloration imparted by the dye permits delineation of the vessels against the surrounding tissue.</p></div>
<div class="block phk drugH1Div" id="F5577211"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (up to 10%; as unchanged drug within 24 hours of administration) </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58202406"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Patentblau v</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Lymphazurin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-25091718">
<a name="25091718"></a>Baker MG, Cronin JA, Borish L, Lawrence MG. Evaluation of a skin testing protocol for diagnosing perioperative anaphylaxis due to isosulfan blue allergy.<i> Ann Allergy Asthma Immunol</i>. 2014;113(3):330-331.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosulfan-blue-dye-drug-information/abstract-text/25091718/pubmed" id="25091718" target="_blank">25091718</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Isosulfan blue [prescribing information]. Rockford, IL: Mylan Institutional; December 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27444110">
<a name="27444110"></a>James TA, Coffman AR, Chagpar AB, et al. Troubleshooting sentinel lymph node biopsy in breast cancer surgery. <i>Ann Surg Oncol</i>. 2016;23(11):3459-3466. doi:10.1245/s10434-016-5432-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosulfan-blue-dye-drug-information/abstract-text/27444110/pubmed" id="27444110" target="_blank">27444110</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ortiz D, Alvikas J, Riker AI. A case of severe anaphylactic reaction secondary to isosulfan blue dye injection. <i>Ochsner J</i>. 2015; 15(2):183-186.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25612264">
<a name="25612264"></a>Reed H, Shaw C, Rice M, Le HT. Isosulfan blue dye anaphylaxis presenting as impaired ability to ventilate via a laryngeal mask airway. <i>A A Case Rep</i>. 2014;3(1):1-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/isosulfan-blue-dye-drug-information/abstract-text/25612264/pubmed" id="25612264" target="_blank">25612264</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9039 Version 103.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
